12/5
08:00 am
urgn
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/25
09:08 am
urgn
UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
Low
Report
UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
11/25
08:00 am
urgn
UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference
Low
Report
UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference
11/16
10:26 pm
urgn
UroGen Pharma (URGN) Closes Q3 2025 With $127.4 Million in Cash Amid Rising R&D Costs [Yahoo! Finance]
Low
Report
UroGen Pharma (URGN) Closes Q3 2025 With $127.4 Million in Cash Amid Rising R&D Costs [Yahoo! Finance]
11/9
08:55 am
urgn
Analysts Have Made A Financial Statement On UroGen Pharma Ltd.'s (NASDAQ:URGN) Third-Quarter Report [Yahoo! Finance]
Low
Report
Analysts Have Made A Financial Statement On UroGen Pharma Ltd.'s (NASDAQ:URGN) Third-Quarter Report [Yahoo! Finance]
11/6
10:28 pm
urgn
UroGen Pharma Ltd. (URGN) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
UroGen Pharma Ltd. (URGN) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/6
04:40 pm
urgn
UroGen Pharma Ltd (URGN) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ... [Yahoo! Finance]
Low
Report
UroGen Pharma Ltd (URGN) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ... [Yahoo! Finance]
11/6
08:00 am
urgn
UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum
High
Report
UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum
11/6
07:58 am
urgn
UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial
High
Report
UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial
11/4
08:00 am
urgn
UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference
Medium
Report
UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference
10/30
08:00 am
urgn
UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025
Low
Report
UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025
10/27
11:23 am
urgn
Urogen Pharma (NASDAQ:URGN) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Medium
Report
Urogen Pharma (NASDAQ:URGN) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
10/27
08:44 am
urgn
Urogen Pharma (NASDAQ:URGN) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
Medium
Report
Urogen Pharma (NASDAQ:URGN) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
10/27
08:00 am
urgn
Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026
Medium
Report
Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026
10/18
01:31 am
urgn
Urogen Pharma (NASDAQ:URGN) was downgraded by analysts at
Wall Street Ze
Medium
Report
Urogen Pharma (NASDAQ:URGN) was downgraded by analysts at
Wall Street Ze
10/3
08:47 am
urgn
Urogen Pharma (NASDAQ:URGN) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
Low
Report
Urogen Pharma (NASDAQ:URGN) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
10/2
08:05 am
urgn
ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer [Yahoo! Finance]
Medium
Report
ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer [Yahoo! Finance]
10/2
08:00 am
urgn
ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer
Medium
Report
ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer
9/13
01:06 am
urgn
Medium
Report
9/8
08:25 am
urgn
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
High
Report
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
9/8
08:00 am
urgn
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
High
Report
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)